Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer

Abstract

Relapsed ovarian cancers harbor more predicted neoantigens than primary tumors, but the increase is due to pre-existing mutational processes, not mutagenesis from chemotherapy.